Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Stefan Wietek"'
Autor:
Atul T Patel, Mark F Lew, Khashayar Dashtipour, Stuart Isaacson, Robert A Hauser, William Ondo, Pascal Maisonobe, Stefan Wietek, Bruce Rubin, Allison Brashear
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0250475 (2021)
[This corrects the article DOI: 10.1371/journal.pone.0245827.].
Externí odkaz:
https://doaj.org/article/678fa54813e44fa6aee14de2d0af6f97
Autor:
Atul T Patel, Mark F Lew, Khashayar Dashtipour, Stuart Isaacson, Robert A Hauser, William Ondo, Pascal Maisonobe, Stefan Wietek, Bruce Rubin, Allison Brashear
Publikováno v:
PLoS ONE, Vol 16, Iss 2, p e0245827 (2021)
Cervical dystonia (CD) is primarily treated with botulinum toxin, at intervals of ≥ 12 weeks. We present efficacy, patient-reported outcomes (PROs), and safety in adults with CD at the last available visit after a single set of abobotulinumtoxinA (
Externí odkaz:
https://doaj.org/article/a5449450af90414086d5fdfeaf325785
Autor:
Mark F. Lew, Robert A. Hauser, Stuart H. Isaacson, Daniel Truong, Atul T. Patel, Allison Brashear, William Ondo, Pascal Maisonobe, Khashayar Dashtipour, Laxman Bahroo, Stefan Wietek
Publikováno v:
Clinical Parkinsonism & Related Disorders, Vol 5, Iss , Pp 100115- (2021)
Introduction: Cervical dystonia (CD) is a neurologic movement disorder with potentially disabling effects and significant impact on quality of life of those affected. AbobotulinumtoxinA (aboBoNT-A) was initially approved for a dilution of 500 U/1 mL
Externí odkaz:
https://doaj.org/article/1b10f3346552463da42e87acfb171361
Autor:
Pascal Maisonobe, Bruce Rubin, Khashayar Dashtipour, Richard Trosch, Stefan Wietek, Laxman B. Bahroo
Publikováno v:
Journal of Clinical Movement Disorders, Vol 7, Iss 1, Pp 1-7 (2020)
Journal of Clinical Movement Disorders
Journal of Clinical Movement Disorders
Background Cervical dystonia (CD), the most common focal dystonia, is a chronic neurological movement disorder characterized by sustained involuntary contractions of the neck muscles, leading to abnormal postures. AbobotulinumtoxinA (aboBoNT-A) was a
Autor:
Allison Brashear, Stefan Wietek, Stuart Isaacson, William G. Ondo, Mark F. Lew, Pascal Maisonobe, Bruce K. Rubin, Robert A. Hauser, Khashayar Dashtipour, Atul T. Patel
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 2, p e0245827 (2021)
PLoS ONE, Vol 16, Iss 4, p e0250475 (2021)
PLoS ONE, Vol 16, Iss 2, p e0245827 (2021)
PLoS ONE, Vol 16, Iss 4, p e0250475 (2021)
Cervical dystonia (CD) is primarily treated with botulinum toxin, at intervals of ≥ 12 weeks. We present efficacy, patient-reported outcomes (PROs), and safety in adults with CD at the last available visit after a single set of abobotulinumtoxinA (
Autor:
Stefan Wietek
Publikováno v:
Neurodegenerative Disease Management
Aim: To present data from three studies of a Post-Authorization Safety Surveillance (PASS) program for the subset of patients receiving Octagam® 5% or 10% for chronic inflammatory demyelinating polyneuropathy (CIDP). Methods: Data on patients with C
Publikováno v:
Hematology. 23:242-247
Objectives To provide detailed data on the tolerability and safety of octagam® 10%, a ready-to-use intravenous immunoglobulin, in a subgroup of patients with immune thrombocytopenia (ITP) involved in an integrated analysis of post-authorisation safe
Publikováno v:
International Journal of Clinical Pharmacology and Therapeutics
Objective To evaluate the tolerability and safety of Octagam® 5% and 10% across all indications, ages, and treatment regimens, using data from four non-interventional post-authorization safety studies (PASS); this analysis was performed following ch
Autor:
Robert A. Hauser, William G. Ondo, Laxman B. Bahroo, Mark F. Lew, Daniel Truong, Atul T. Patel, Allison Brashear, Pascal Maisonobe, Stefan Wietek, Stuart Isaacson, Khashayar Dashtipour
Publikováno v:
Clinical Parkinsonism & Related Disorders, Vol 5, Iss, Pp 100115-(2021)
Clinical Parkinsonism & Related Disorders
Clinical Parkinsonism & Related Disorders
Highlights • Cervical dystonia has significant impact on quality of life of those affected. • Dilution options allow for treatment flexibility and individualized patient care. • AboBoNT-A is efficacious with similar safety and tolerability at e
Publikováno v:
Toxicon. 190:S57